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ABSTRACT 
BACKGROUND 
With the advent of anti-fibrotic therapies, the distinction between IPF and other ILDs 
has become central to accurate management. We conducted an international study 
of IPF diagnosis among a large group of physicians with different levels of 
experience and compared their diagnostic performance to a panel of IPF experts. 
Candidate factors impacting diagnostic accuracy were evaluated. 
METHODS 
3423 respiratory physicians from 102 countries and a panel of international IPF 
experts (n=34) were invited to participate. Participants were required to evaluate 60 
consecutive cases of interstitial lung disease. Each physician, without inter-
disciplinary consultation, selected up to five differential diagnoses and chose 
likelihoods for each of their differential diagnoses. Diagnostic agreement was 
measured using Cohen’s kappa coefficient (κ) and the weighted kappa coefficient 
(κw). Prognostic discrimination between IPF and other diffuse lung diseases were 
used to validate diagnostic accuracy for first-choice diagnoses of IPF and were 
compared using the C-index· 
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FINDINGS 
 
404 physicians completed the study. IPF made up 6308 (26·0%) of all first-choice 
diagnoses. Agreement for the diagnostic likelihood of an IPF diagnosis was highest 
among expert physicians (κw =0·65 [IQR 0·53-0·72]), and greater than among 
academic physicians (κw =0.56 [IQR 0.45-0.65], p<0.0001) or among physicians with 
access to multidisciplinary team (MDT) meetings (κw =0.54 [IQR 0.45-0.64], 
P<0.0001). 
 
Academic status, greater than 20 years experience and MDT meeting 
attendance were independently associated with prognostic accuracy of a diagnosis 
of IPF. The prognostic accuracy of academic physicians with greater than 20 years 
experience (C-index=0·72, [IQR 0·0-0·73])) did not differ significantly (p=0·229) from 
the prognostic accuracy of diagnoses of IPF made by the expert panel (C-
index=0·74 [IQR 0·72-0·75]). Prognostic accuracy of non-university hospital 
physicians with more than 20 years experience, attending weekly MDT meetings (C-
index=0·72, [IQR 0·70-0·72]) approached expert-level performance (p=0·052). 
 
 
INTERPRETATION 
 
Academic status, attendance at MDT meetings and greater than 20 years 
experience independently predict the prognostic accuracy of IPF diagnosis among a 
large cohort of respiratory physicians drawn from many countries. Experienced 
respiratory physicians working at university-based institutions make diagnoses of IPF 
with similar prognostic accuracy to an international panel of IPF experts. 
 
 
FUNDING 
 
None. 
INTRODUCTION 
 
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive loss of lung 
function and a particularly poor prognosis 1. Although it is often regarded as a rare 
disorder, in 2012 1% of all deaths in the United Kingdom occurred due to IPF 2 
and the incidence of IPF is expected to continue to rise 3-8. Accurate IPF 
diagnosis has increased in importance with the advent of anti-fibrotic therapies 
and on-going enrolment in IPF treatment trials 9,10. 
 
Although the ATS/ERS/JRS/ALAT guideline diagnostic recommendations 
emphasise the importance of a multidisciplinary (MD) approach when diagnosing IPF 
11-13, less experienced non-academic clinicians outside regional centres may not 
have access to multidisciplinary team meetings14. Therefore, the diagnostic 
accuracy of clinicians acting in isolation is of practical importance. In the absence of 
a reference standard, one approach to evaluating the diagnostic skills of clinicians is 
to examine separations in mortality between patients diagnosed with IPF and those 
diagnosed with other ILDs, a method used in a recent study of MD diagnosis 15. The 
most accurate discrimination between IPF and non-IPF diagnoses should, in 
principle, provide the greatest separation in outcomes. 
 
The aim of this study was to evaluate and compare IPF diagnoses made by 
non-academic clinicians, university-affiliated clinicians and an international panel of 
IPF experts, using three surrogates of diagnostic accuracy: diagnostic confidence, 
diagnostic agreement and prognostic accuracy (which was examined in non-expert 
sub-groups against years of experience and access to an MDT meeting). 
METHODS 
 
 
 
 
Case collection 
 
The study protocol was approved by the NHS Health Research Authority, and for this 
retrospective examination of clinically indicated data, the need for patient consent 
was waived. We selected consecutive patients presenting to the interstitial lung 
disease unit of the Royal Brompton and Harefield NHS Foundation Trust (London, 
United Kingdom) between January 5th, 2010 and October 25th, 2010 (see 
Supplementary Appendix, Figure 1). This approach allowed an analysis of 5-year 
survival and also meant that patients included in the study were selected from a pre-
antifibrotic therapy era. Therefore, outcome distinctions between patients with IPF 
and those without this disease were not confounded by antifibrotic therapy. Since 
referral rates of patients with suspected IPF to the host institution in 2010 differed 
(25% of all referrals) from 2015 (36% of all referrals), we enriched the cohort with 
consecutive patients referred to the host institution between January 5th, 2010 and 
October 25th, 2010 and who were diagnosed with IPF by the host institution, to 
match 2015 IPF referral rates. Exclusion criteria were: 
 
 
 An established diagnosis of connective tissue disease prior to presentation to 
the host institution. In these patients, the diagnosis of connective tissue 
disease-related ILD is usually straightforward and might spuriously increase 
overall diagnostic agreement 15.

 Non-availability of imaging or lung function tests at presentation.

 DLco<30% predicted, excluded because: a) clinicians might assume that the 
presence of end-stage fibrosis indicates IPF thus impacting diagnostic
 
agreement and accuracy for an IPF diagnosis; b) although patients with end-
stage fibrotic lung disease may occasionally be referred to the host institution, 
this may not reflect referral patterns to less specialised centres; c) treatment 
may be less effective in patients with end-stage fibrosis reducing the 
importance of diagnostic precision. 
 
 
Participating physicians 
 
Between January 1st, 2015 and July 1st, 2016 we performed an Internet search, 
country by country, for practising respiratory physicians. Physician experience, 
nationality, academic status (working at a university hospital or not a university 
hospital) or subspecialist interests within respiratory medicine did not influence 
inclusion eligibility. This search included the European Respiratory Society Diffuse 
Parenchymal Lung Disease Assembly and the American Thoracic Society Clinical 
Problems Assembly. During July 2016 an invitation to participate in the study was 
extended to all of the physicians identified. In addition to this group, an expert panel 
was created, comprising of respiratory physicians with specialist expertise in the 
diagnosis and management of interstitial lung disease working in specialist ILD 
centres and with a track record of publications in this field. 
 
 
Scoring Protocol 
 
Evaluation of cases took place between July 1st, 2016 and January 1st, 2017 on a 
custom built web-based application. First, physicians were required to answer a 
preliminary survey regarding their usual clinical practice (Supplementary Appendix, 
Table A1). Then for each case they were presented with the patient’s history, 
findings on physical examination and standardised baseline clinical information, 
 
extracted from the patient electronic records (Supplementary Appendix, Table A2). 
Physicians were provided the presentation high-resolution computed tomography 
scan (HRCT). The original HRCT report was not provided. We did not inform 
physicians if the host institution had performed surgical lung biopsy. Since biopsy 
decisions depend on a physician’s individual clinical judgement, there would be no 
way of knowing which patients would eventually have undergone a lung biopsy. Also, 
if we had provided biopsy information, the clinical skill of the physician would be 
amalgamated with the expertise of the host institution. 
 
The scoring protocol has been described previously 15. For each case, 
physicians were required to select up to 5 differential diagnoses and provide a 
diagnostic likelihood (censored at 5% and summing to 100% in each case) from a 
drop-down menu of diffuse lung diseases (Supplementary Appendix, Table A3). 
The drop-down menu included a category labelled ‘other’, to be selected when the 
desired diagnosis was not listed. In this situation, physicians were required to 
provide their diagnosis in a free-text box. The only stipulation to scoring the cases 
was that each case was evaluated in isolation without inter-specialty consultation. 
 
 
Statistical analysis 
 
Statistical analyses were performed using STATA (version 14, StataCorp, College 
Station, Texas). Data are given as means with standard deviations (SD), medians 
with interquartile range (IQR) or as the number of patients and percentage where 
appropriate. Group comparisons were made using the Student’s t-test, Wilcoxon rank 
sum, Χ2 statistics and Fisher’s exact test where appropriate. 
 
Cohen’s kappa coefficient (κ) was used to evaluate interobserver agreement 
for diagnosis and Cohen’s weighted kappa coefficient (κw) was used to evaluate 
 
interobserver agreement for an estimation of the probability of each diagnosis. In 
order to do this, the percentage diagnostic likelihood given for each diagnosis was 
converted to a 5 point scale (0–4), representing clinically useful probabilities: 0 = 
condition not included in the differential diagnosis, 1 = low probability (5–25%), 2 = 
intermediate probability (30–65%), 3 = high probability (70–95%), and 4 = 
pathognomonic (100%). This approach has been used in previous investigations of 
interobserver agreement for the diagnosis of diffuse lung diseases 15-17 
(Supplementary Appendix, Methods). Additionally, for each patient the first-choice 
diagnosis was considered high confidence if the diagnostic likelihood assigned was 
≥70%. This distinction is based on the diagnostic likelihood categories used to 
assess the clinical probability of pulmonary embolism in the PIOPED study18 and 
has been used in another study of diagnostic agreement 15. 
 
We used outcome distinctions between IPF and other diffuse lung diseases to 
validate diagnostic accuracy for IPF by converting each physician’s first-choice 
diagnosis into a binary IPF diagnosis category (IPF or not IPF) and determining its 
prognostic significance using Cox proportional hazards modelling. The hazards 
ratios were adjusted for disease severity by including percent predicted DLco in the 
regression model. Results are reported as HRs, 95% CIs, and p values. A p value of 
<0·05 was considered statistically significant. The prognostic accuracy of individual 
physician diagnoses was quantified using Harrell’s C-index, which when used in this 
context, is a measure of prognostic discrimination (Supplementary Appendix, 
Methods)19. Multivariate linear regression models were used to identify independent 
predictors of prognostic accuracy, using a backward elimination procedure and 
retaining variables with p values <0·05. The assumptions of linear regression were 
tested and confirmed by inspection of residual-versus-predictor plots and 
 
heteroskedasticity was tested for graphically (by inspection of residuals plotted 
against fitted values) and non-graphically (using the Cook-Weisberg test for 
heteroskedasticity). The diagnostic performance of various subgroups of physicians 
based on these predictors was then compared to the expert panel group. 
 
 
 
 
 
RESULTS 
 
Patient population and participating physicians 
 
The total cohort of cases was made up of 60 patients, including 22 (36·7%) with an 
MDT meeting diagnosis of IPF. Five patients required surgical lung biopsy. Three of 
these were diagnosed as IPF, one as pulmonary alveolar proteinosis and one as 
obliterative bronchiolitis. Vital status was known for all patients at the end of the 
study period. There were 26/60 (43·4%) deaths at the end of the study period. Mean 
follow-up period for IPF and non-IPF cases were 1246.0 days and 1646.0 days 
respectively. For more details of patient exclusions, diagnoses and mortality, see 
the Supplementary Appendix (Results Section and Table A4). 
 
A total of 3423 respiratory physicians from 102 countries were invited to 
participate in the study. Between July 7th, 2016 and January 1st, 2017, 750 
physicians representing 76 countries enrolled and completed the preliminary survey. 
Of these, 404 physicians, representing 57 countries, which included a panel of 34 
invited experts, completed the evaluation of all 60 cases. Physicians who completed 
the study were more likely to be fellowship trained, work at university hospitals, have 
access to MDT meetings, and diagnose more cases of IPF per month (Table 1 and 
Table 2). A summary of physician demographics based on country is shown in the 
supplementary material (Table A5). 
Frequency of IPF diagnosis and diagnostic confidence 
 
A total of 24240 case evaluations were performed (404 physicians x 60 cases). IPF 
made up 6308 (26·0%) of all first-choice diagnoses. 72·3% of IPF diagnoses were 
made with high confidence (diagnostic likelihood ≥ 70%). Expert panel members and 
academic physicians made high confidence diagnoses of IPF more frequently than 
non-academic physicians (P=0·002 and P=0·001, Table 3) and more frequently 
diagnosed IPF overall (P=0·005 and P=0·008, Table 3). Attendance at MDT 
meetings was not associated with a higher frequency of IPF diagnoses or a higher 
frequency of highly confident IPF diagnoses (P=0·718, P=0·925, Table 3). 
 
 
 
 
Diagnostic agreement 
 
Overall interobserver agreement for the first-choice diagnosis of IPF was moderate 
for the entire cohort of physicians (n=404, K=0·42). Unweighted Kappa values for 
interobserver agreement for a diagnosis of IPF for various physician subgroups are 
shown in Table 4. The greatest diagnostic agreement for the first-choice diagnosis of 
IPF was between the expert panel members (n=34, K=0·53). Physicians with no 
access to MDT meetings had the lowest level of diagnostic agreement for the first-
choice diagnosis of IPF (n=76, K=0·35) (Table 4). Agreement on the likelihood of an 
IPF diagnosis (ranging from <5% to >95%) was highest among expert physicians, 
academic physicians and physicians with access to MDT meetings (Table 5). Inter-
observer agreement for the likelihood of an IPF diagnosis between physicians based 
on country is shown in the supplementary material (Table A6). 
Prognostic accuracy of an IPF diagnosis 
 
Diagnoses of IPF were prognostically significant for 318 of 404 respiratory 
physicians (68·6%, median HR=2·81 [IQR 2·21-3·61], median C-index=0·72 [IQR 
0·70-0·74]). Hazards ratios, p values and C-indices for all participating physicians 
based on country are shown in the supplementary material (Supplementary 
Appendix, Table A7). Expert physicians, compared to other physicians, were more 
likely to make prognostically significant IPF diagnoses (29/34, 85·2%, versus 
246/370, 66·4%, p=0·02) and with greater prognostic discrimination (as judged by 
C-indices), p=0·0002 (Supplementary Appendix, Table A8). Academic physicians 
demonstrated greater prognostic discrimination for a diagnosis of IPF than non-
university based hospital physicians, p=0·0006 (Table A9). Physicians who attend 
MDT meetings demonstrated greater prognostic discrimination for a diagnosis of IPF 
than physicians not attending MDT meetings, p=0·004, Table A10). 
 
Multivariate linear regression analysis was performed taking the C-index as the 
dependent variable and 1) academic status, 2) years experience (stratified by 
thresholds ranging from 5-35 years in 5 year increments), 3) MDT meeting attendance 
and 4) number of IPF cases diagnosed per month as the independent variables. 
Academic status, >20 years experience and attendance at MDT meetings 
independently predicted the prognostic accuracy of IPF diagnosis (Supplementary 
appendix, A11). Subsequent analyses of particular interest are summarised in Table 
6. Specifically, 
 
1. University hospital physicians with >20 years of experience achieved 
equivalent prognostic discrimination to the expert panel for a diagnosis of IPF 
(or not IPF group), regardless of attendance at weekly MDT meetings (Table 
6). 
 
2. Non-university hospital physician prognostic discrimination did not reach that 
of the expert panel, regardless of availability of MDT meetings or the 
threshold of 20 years of experience (Table 6). However, non-university 
hospital physicians with >20 years of experience, attending weekly MDT 
meetings, demonstrated near expert level prognostic accuracy (C-index 0·72 
(IQR 0·70-0·72), p=0·052). 
 
 
 
 
 
DISCUSSION 
 
Our results show that academic status, attendance at MDT meetings and experience 
level of physicians are independently associated with greater prognostic 
discrimination between diagnoses of IPF and other ILDs. In particular, using 
mortality to validate accuracy of IPF diagnosis, we have shown that accuracy of IPF 
diagnosis made by university hospital-based practitioners with greater than 20 years 
experience is equivalent to that of international IPF experts. 
 
A recent study reported near parity in diagnostic agreement and accuracy for 
IPF between expert physicians and their respective MDT meetings 15. The purpose 
of this study was to investigate whether these findings could also be applied to 
physicians of varying levels of experience when acting in isolation without the benefit 
of MDT meeting evaluation. A central feature of our study was that we validated IPF 
diagnosis against mortality, an approach used in a previous study of diagnostic 
agreement and accuracy in IPF 15. In diffuse lung disease, multidisciplinary 
discussion is the recommended approach to diagnosis, which involves integrating all 
available clinical, radiologic and if available, pathologic data. For this reason, there is 
no reference standard against which the veracity of MDT diagnosis can be tested. 
 
However, as a poor outcome is a cardinal feature of IPF, accurate diagnosis should, 
in principle, provide the greatest prognostic discrimination between IPF and other 
interstitial lung diseases. 
 
Although several studies have reported that MDT diagnosis is associated with 
higher levels of diagnostic confidence and superior interobserver agreement when 
compared to the individual components of the MDT in isolation 15,20,21, the effect 
that MDT meetings have on individuals has not been examined. One of the assumed 
benefits of a multidisciplinary approach to IPF diagnosis is that those participating 
have their diagnostic thinking subjected to public scrutiny. The regular inter-specialty 
discussion that MDT meetings promote is likely to broaden a physician's experience 
and establish an ethos of debate and critical evaluation. Conceivably, physicians 
who are accustomed to this process gain skill in related disciplines such as HRCT 
interpretation, which they can use outside the multidisciplinary setting. For some 
physicians, increasing patient numbers and possibly referrals from other centres will 
mean that full MDT meeting characterization is possible only for selected cases. 
Therefore, just as in this study, it is likely that a substantial number of IPF patients 
will receive a diagnosis made by their respiratory physician acting in isolation. In a 
recent national survey conducted in France, IPF diagnosis resulted from 
multidisciplinary discussion in only 50% of cases22. It is noteworthy that in the 
current study, 43% of completing physicians stated that in most cases of suspected 
IPF, they made the diagnosis by themselves with the aid of diagnostic guidelines. 
We demonstrate that weekly MDT meeting attendance among experienced non-
university hospital physicians increased prognostic accuracy of IPF diagnosis to that 
achieved by IPF experts. 
 
Our findings may have implications for future multidisciplinary practice. Based 
on several studies of diagnostic agreement and accuracy over the past decade, MDT 
evaluation of IPF has become enshrined in the literature as the optimum approach to 
diagnostic synthesis 1,12,13,15,20,23,24. A difficulty implementing this 
recommendation is that local access to multidisciplinary expertise may be limited. 
One possible solution to this problem is to network with academic centres using 
different forms of telemedicine. Since the web-based evaluation of patients in this 
study to some extent replicates telemedicine methodologies, our findings provide 
support for telemedicine as an acceptable form of multidisciplinary practice 24,25. 
Such collaboration could also include guidance on setting up local community 
hospital MDT meetings or having community physicians attend MDT meetings at 
local university hospitals. 
 
Our study has some unavoidable limitations, common to previous studies of 
multidisciplinary practice 15-17. First, unlike real-world clinical practice, it was 
impractical for physicians to engage in face-to-face consultation with patients, 
meaning that doctors did not have the chance to take a clinical history or examine 
the patients themselves. In complex disease, direct contact with the patient may 
influence a clinician’s impression in a manner that is not easy to quantify objectively. 
However, direct patient contact in a study of this size would have been impracticable. 
Our methodology of web-based case reviews is instead similar to that of previously 
published studies of diagnostic agreement and accuracy between MDT meetings 
15,20,26. Second, physicians who completed the study were more likely to be 
fellowship trained, work at university institutions, attend MDT meetings and diagnose 
more cases of IPF per month. Nevertheless, sufficient numbers of physicians 
working in non-university institutions and without access to MDT meetings took part 
 
in our study, allowing us to perform statistically meaningful analyses in these 
subgroups. Third, to our knowledge no guideline recommendation indicates what 
precisely constitutes a valid MDT meeting. Although we asked physicians if they 
participated in formal MDT meetings, we did not attempt to quantify informal inter-
specialty consultation, which might also be considered by some to be a form of 
multidisciplinary practice27. An investigation to identify the optimum MDT meeting 
format could be the focus of future investigation. 
 
In conclusion, our study indicates that diagnostic agreement for IPF is 
acceptable between a large group of respiratory physicians of varying degrees of 
experience and drawn from a wide range of geographic locations. However, 
experienced respiratory doctors who work at university-based institutions show 
greater agreement on a diagnosis of IPF and make greater prognostic distinctions 
between IPF and other diffuse lung diseases than those at non-university institutions. 
Importantly, the diagnostic performance of experienced non-university practitioners 
improves with regular MDT meetings. These results may be a stimulus for greater 
interaction between university and community hospitals as well as the development 
of local MDT meetings for the specific purpose of assessing patients with suspected 
IPF. 
 
 
Research in context 
 
Evidence before this study 
 
We performed a PubMed search on 1
th
 January 2017 using the search terms “diffuse 
parenchymal lung disease”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial 
pneumonias”, “interobserver agreement”, “diagnosis”, “usual interstitial pneumonia”, 
“pulmonary fibrosis”, “multidisciplinary team” and “diagnostic accuracy” for the period 
 
between January 2000 and January 2017. Our search was restricted to publications 
written in English. We identified 12 key publications, which were pertinent to our study. 
Of these, 4 studies of diagnostic performance in setting of idiopathic pulmonary fibrosis 
(IPF) were identified. All of these 4 studies either predate the current 
ATS/ERS/JRS/ALAT guideline statement on the diagnosis and management of IPF or 
specifically evaluated multidisciplinary team meeting diagnosis of IPF. 
 
 
Added value of this study 
 
Our study is the first evaluation of diagnostic confidence, diagnostic agreement and 
prognostic accuracy for a clinical diagnosis of IPF among a large international group 
of respiratory physicians since the updated 2013 ATS/ERS classification of the 
idiopathic interstitial pneumonias and the 2011 ATS/ERS/JRS/ALAT guidelines for 
the diagnosis and management of IPF. Candidate factors, which impact diagnostic 
performance, including academic status, experience and in particular, attendance at 
multidisciplinary meetings were evaluated. 
 
 
Implications of all the available evidence 
 
Our study indicates that diagnostic agreement for IPF is acceptable between a large 
group of respiratory physicians of varying degrees of experience and drawn from a 
wide range of geographic locations. Experienced respiratory physicians who work at 
university-based institutions show greater agreement on a diagnosis of IPF and 
make sharper prognostic distinctions between IPF and other diffuse lung diseases 
than those at non-university institutions. The diagnostic performance of experienced 
non-university practitioners improves if access to regular MDT meetings is available. 
Our results may be a stimulus for increased collaboration between university and 
community hospitals and encourage the development of local MDT meetings for the 
 
specific purpose of assessing patients with suspected IPF. 
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Completed 
Did Not  
 
 
Question Complete P Value   (n=404)    (n=346)        
 
       
 
 Years experience  15·8  15·7 0·565 
 
 ILD Fellowship training      
 
 Yes 359 (88·9%) 283 (70·0%) 0·006 
 
 In-training 17 (4·2%) 20 (5·8%) 0·322 
 
 No 28 (6·9%) 43 (12·4%)  
 
 Hospital setting      
 
 University 288 (71·3%) 207 (59·8%) 0·001 
 
 Not university 116 (28·7%) 139 (40·2%)  
 
 MDT meeting      
 
 MDT meeting access 328 (81·2%) 247 (61·8%) 0·002 
 
 No MDT meeting access 76 (18·8%) 99 (28·6%)  
 
 Number of cases of IPF      
 
 diagnosed/month      
 
 None, we refer all cases of      
 
 suspected IPF to an academic 20 (5·0%) 38 (11·0%) 0·002 
 
 centre      
 
 1-10 337 (83·4%) 290 (83·8%) 0·883 
 
 11-20 37 (9·2%) 12 (3·5%) 0·002 
 
 20+ 9 (2·2%) 5 (4·1%) 0·430 
 
 Access to specialist      
 
 radiology expertise      
 
 None 22 (5·4%) 26 (7·5%) 0·191  
  
 
 Not directly but in my network 60 (14·9%) 58 (16·8%) 0·474  
  
 
 Yes 322 (79·7%) 262 (75·7%) 0·248  
  
 
 Access to specialist      
 
 pathology expertise      
 
 None 34 (8·4%) 35 (10·1%) 0·006  
  
 
 Not directly but in my network 85 (21·0%) 100 (28·9%) 0·013 
 
 Yes 285 (70·5%) 211 (61·0%) 0·422  
  
 
 Availability of cryobiopsy      
 
 Yes 65 (16·1%) 44 (12·7%) 0·191 
 
 No 339 (83·9%) 302 (87·3%)  
 
       
 
 
 
Table 1. Responses to the preliminary survey by 404 physicians who 
completed the study and the 346 physicians who did not completed the study. 
ILD= interstitial lung disease. 
  
University 
Not  
 
  
University 
 
 
 
Grouping Hospital P Value   
Hospital    
(n=288) 
 
 
  
(n=116) 
 
 
    
 
     
 
 Experience (years) 14·9 17·8 0·009 
 
 Fellowship trained 251 108 0·085 
 
 MDT meeting practices    
 
 No MDT meeting 41 35 0·001 
 
 Daily MDT meeting 4 0 0·202 
 
 Weekly MDT meeting 118 25 0·001 
 
 Fortnightly MDT meeting 41 8 0·021 
 
 Monthly MDT meeting 66 34 0·178 
 
 Less than 1/month MDT meeting 18 14 0·05 
 
 Number of IPF cases diagnosed/month    
 
 Refer all cases of suspected IPF 14 6 0·896 
 
 1-10 cases 234 103 0·065 
 
 11-20 cases 32 5 0·032 
 
 More than 20 cases 7 2 0·663 
 
 Access to radiology expertise    
 
 Direct access 242 80 0·001 
 
 Access through network 35 25 0·016 
 
 No access 11 11 0·023 
 
 Access to pathology expertise    
 
 Direct access 219 66 0·001 
 
 Access through network 49 36 0·002 
 
 No access 20 14 0·093 
 
 Cryobiopsy part of usual practice 54 11 0·022 
 
     
 
 
Table 2. Responses to the preliminary survey by 404 physicians grouped 
according to institution type (University hospital or not university hospital). 
MDT = multidisciplinary team, IPF = idiopathic pulmonary fibrosis. 
  
 Expert Panel 
Others 
 
 
  
physicians P Value    
(n=370)    
(n=34) 
 
 
    
 
     
 
 Median number of IPF 
20 (IQR14-23) 15 (IQR 11-19) 0·005   diagnoses      
 
 *Median number of high 
17 (IQR8-21) 11 (IQR 7-14) 0·002   confidence IPF diagnoses      
 
     
 
 
University Hospital 
Not University  
 
  
Hospital 
 
 
  Physicians P Value    Physicians    
(n=288) 
 
 
  
(n=116) 
 
 
    
 
 
Median number of IPF 
   
 
 
16 (IQR12-20) 13 (IQR10-19) 0·008   diagnoses      
 
 *Median number of high 
11 (IQR 8-16) 9 (IQR 6-12) 0·001   confidence IPF diagnoses      
 
     
 
 MDT Meeting No MDT Meeting  
 
  Attendance Attendance P Value 
 
  (n=328) (n=76)  
 
 
Median number of IPF 
   
 
 
15 (IQR11-20) 15 (IQR10-20) 0·925   diagnoses      
 
 *Median number of high 
11 (IQR 7-15) 11 (IQR 6·5-15) 0·718   confidence IPF diagnoses      
 
     
 
 
Table 3. Median number of IPF diagnoses made and median number of high 
confidence IPF diagnoses made for individual physicians by subgroup. All 
values are out of 60 cases. *High confidence diagnoses are defined as those 
cases assigned a diagnosis of IPF with a diagnostic likelihood of 70%. 
  
Group 
Interobserver 
 
 Agreement (κ)    
 
   
 
 Physicians, expert panel (n=34) 0·53 
 
 Physicians, non expert panel (n=370) 0·41 
 
 University physicians (n=288) 0·43 
 
 Non-university physicians (n=116) 0·38 
 
 Physicians with MDT meeting access (n=328) 0·44 
 
 Physicians without MDT meeting access (n=76) 0·35 
 
   
 
 
 
Table 4. Unweighted Kappa values (κ) for interobserver agreement for a 
diagnosis of idiopathic pulmonary fibrosis for various physician subgroups. 
Group Comparisons 
Interobserver 
P value  
Agreement (κw)    
 
   
 
Physicians, 
0·65 (IQR 0·53-0·72) 
 
 
expert panel (n=34)     
 
  <0·001 
 
Remaining 
0·53 (IQR 0·41-0·63) 
 
 
Physician group (n=370)     
 
   
 
University hospital 
0·56 (IQR 0·45-0·65) 
 
 
physicians (n=288)     
 
  <0·001 
 
Non-university hospital 
0·49 (IQR 0·38-0·59) 
 
 
physicians (n=116)     
 
   
 
MDT meeting 
0·54 (IQR 0·45-0·64) 
 
 
available (n=328)     
 
  <0·001 
 
No MDT meeting 
0·48 (IQR 0·35-0·59) 
 
 
available (n=76)     
 
   
 
 
Table 5. Comparisons of weighted Kappa values (κw) for interobserver 
agreement on the diagnostic likelihood of a diagnosis of idiopathic pulmonary 
fibrosis between various subgroups. 
  University hospital physicians Non-university hospital physicians 
 
      
 
 Group C-index P Value* Group C-index P Value* 
 
      
 
 >20 years   >20 years   
 
 experience, 
0·72 
 experience, 
0·70 
 
 
 
no MDT 0·229 no MDT 0·008   
(0·70-0·73) (0·70-0·73)   
meeting 
 
meeting 
 
 
     
 
 (n=11)   (n=18)   
 
 >20 years   >20 years   
 
 experience, 
0·72 
 experience, 
0·71 
 
 
 
MDT 0·116 MDT 0·019   
(0·71-0·75) (0·70-0·73)   
meeting 
 
meeting 
 
 
     
 
 (n=51)   (n=24)   
 
 <20 years   <20 years   
 
 experience, 
0·71 
 experience, 
0·70 
 
 
 
no MDT <0·001 no MDT <0·001   
(0·70-0·72) (0·70-0·71)   
meeting 
 
meeting 
 
 
     
 
 (n=30)   (n=17)   
 
 <20 years   <20 years   
 
 experience, 
0·72 
 experience, 
0·71 
 
 
 
MDT 0·001 MDT <0·001   
(0·70-0·74) (0·69-0·72)   meeting  meeting        
 
 (n=167)   (n=52)   
 
       
 
 
Table 6. Prognostic accuracy expressed as the C-index for diagnosis of IPF or 
not IPF given by various physician subgroups. P values are based upon a 
group comparison with the expert panel (n=34, C-index = 0·74 (0·72-0·75)). 
MDT= multidisciplinary team. 
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